J9043 Cabazitaxel injection
Also known as: cabazitaxel, Jevtana
Intravenous injection of cabazitaxel, a taxane chemotherapy agent derived from semisynthesis.
In Plain Language
microtubule-stabilizing cancer drug; advanced prostate cancer treatment
Clinical Context
Used for hormone-refractory metastatic prostate cancer. Third-generation taxane with activity in docetaxel-resistant disease.
RVU Information
CPT J9043 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9043?
CPT J9043 (Cabazitaxel injection) is a J Codes (Drugs) code. Intravenous injection of cabazitaxel, a taxane chemotherapy agent derived from semisynthesis.
How is J9043 administered?
CPT J9043 is administered by a healthcare provider, typically via injection or infusion. Used for hormone-refractory metastatic prostate cancer. Third-generation taxane with activity in docetaxel-resistant disease. It is used by Oncology, Urology.
When is CPT J9043 used?
Used for hormone-refractory metastatic prostate cancer. Third-generation taxane with activity in docetaxel-resistant disease.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.